Greco F A, Hainsworth J D
Sarah Cannon-Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, TN 37203, USA.
Semin Oncol. 1999 Feb;26(1 Suppl 2):129-33.
Patients with carcinoma of unknown primary site represent a very heterogeneous clinicopathologic group. Progress has been made in defining important clinical subsets, and specialized pathologic analysis is essential for the poorly differentiated neoplasms. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a broad-spectrum antineoplastic agent with demonstrated activity in a wide variety of carcinomas. We have combined paclitaxel with carboplatin and oral etoposide for the therapy of patients with unknown primary carcinoma. The overall response rate (47%, with 13% complete responders) compares favorably with any other chemotherapy. Furthermore, the median survival of 13.4 months was notable and encouraging. Toxicity was well-tolerated and no treatment-related deaths occurred. Additional data are needed to more firmly establish the role of paclitaxel for unknown primary cancer.
原发部位不明的癌患者代表了一个非常异质性的临床病理群体。在定义重要的临床亚组方面已取得进展，对于低分化肿瘤，专门的病理分析至关重要。紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）是一种广谱抗肿瘤药物，已证明在多种癌症中具有活性。我们将紫杉醇与卡铂和口服依托泊苷联合用于治疗原发癌不明的患者。总体缓解率（47%，其中13%为完全缓解者）与任何其他化疗相比都具有优势。此外，13.4个月的中位生存期值得注意且令人鼓舞。毒性耐受性良好，未发生与治疗相关的死亡。需要更多数据来更确切地确立紫杉醇在原发不明癌症中的作用。
